anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND & AIMS: Putative anion transporter-1 (PAT1, SLC26A6) plays a key role in intestinal oxalate and bicarbonate secretion. PAT1 knockout (PKO) mice exhibit hyperoxaluria and nephrolithiasis. Notably, diseases such as inflammatory bowel disease are also associated with higher risk of hyperoxaluria and nephrolithiasis. However, the potential role of PAT1 deficiency in gut-barrier integrity and susceptibility to colitis is currently elusive.
METHODS: Age-matched PKO and wild-type littermates were administered 3.5% dextran sulfate sodium in drinking water for 6 days. Ileum and colon of control and treated mice were harvested. Messenger RNA and protein expression of tight junction proteins were determined by reverse transcription polymerase chain reaction and western blotting. Severity of inflammation was assessed by measuring diarrheal phenotype, cytokine expression, and hematoxylin and eosin staining. Gut microbiome and associated metabolome were analyzed by 16S ribosomal RNA sequencing and mass spectrometry, respectively.
RESULTS: PKO mice exhibited significantly higher loss of body weight, gut permeability, colonic inflammation, and diarrhea in response to dextran sulfate sodium treatment. In addition, PKO mice showed microbial dysbiosis and significantly reduced levels of butyrate and butyrate-producing microbes compared with controls. Co-housing wild-type and PKO mice for 4 weeks resulted in PKO-like signatures on the expression of tight junction proteins in the colons of wild-type mice.
CONCLUSIONS: Our data demonstrate that loss of PAT1 disrupts gut microbiome and related metabolites, decreases gut-barrier integrity, and increases host susceptibility to intestinal inflammation. These findings, thus, highlight a novel role of the oxalate transporter PAT1 in promoting gut-barrier integrity, and its deficiency appears to contribute to the pathogenesis of inflammatory bowel diseases.
Various embodiments provide methods and systems for the biphasic iontophoretic transdermal delivery of therapeutic agents. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient. Embodiments may be used for delivery of agents which cause adverse effects from unwanted passive diffusion.
Attention deficit with hyperactivity disorder (ADHD) is a common childhood mental disorder that affects 3% to 5% of all American children. Symptoms of ADHD commonly include inability to focus or exercise normal inhibition, and in some cases, aggressive behavior. Approximately 33% to 50% of children with ADHD develop oppositional defiant disorder (ODD), and about 20% to 40% develop a conduct disorder (CD). These disorders are characterized by defiant, belligerent, and otherwise aggressive behavior. Treatment for ADHD generally includes use of stimulant medications that decrease impulsivity and increase attentiveness, such as methylphenidate (Ritalin) or dextroamphetamine (Dexedrine), but these do not always affect aggression. To treat aggression in ADHD, many physicians prescribe additional medications, including the mood stabilizing medication valproate and the antipsychotic medication risperidone.

There is no clinical evidence proving that using multiple types of medications is safe and effective. This study will treat children with ADHD and aggression with a combination of stimulants and antipsychotic or mood stabilizing medications to determine whether the aggressive behaviors and ADHD symptoms are reduced without harmful side effects.

This study has two phases. During the first phase, which will last 3 to 6 weeks, participants will be treated with normal ADHD stimulant medications. During the second phase, those whose aggressive behavior is not effectively suppressed by stimulant medication alone will then be randomly assigned to also receive valproate, risperidone, or placebo for 8 weeks. After 8 weeks, children whose aggression persists will be switched from either valproate to risperidone or risperidone to valproate for another 8 weeks. Those on placebo will not switch medications. All participants will attend weekly monitoring visits for 11 to 16 weeks over the course of the study. At these visits, aggression levels and medication side effects will be assessed. Families will also meet with the researchers to discuss the child's progress and will attend behavioral counseling with a therapist.
Group A (Beating heart) surgery was performed under normal temperature (36⁰ C) ,once CPB was established, the patient was placed in Trendelenburg position and a retrograde perfusion catheter was inserted into the coronary sinus and ligated by a simple suture line. Aorta cross clamping was immediately established and blood was oxygenated and delivered continuously through a catheter Mitral valve was exposed using the left atrial retractor. Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
Participants will have blood pressure in both arms measured three times using standard methods. The investigators will then fit the Bio-Z watch onto the non-dominant hand's wrist and the Finapres Nova® on the middle finger of the arm with the Bio-Z device. Participants will be asked to perform different exercises and blood pressure readings will be recorded during the exercise and recovery. Each exercise will be repeated three times. 15 Participants will have the option to complete study procedures twice more, spaced one week apart, for a total of three weeks of participation. Each visit will take at most 2 hours to complete study exercises for a total of 6 hours of study time if all the three visits are completed.
The prevalence of cardiovascular diseases increases with age. Common symptoms such as dyspnea, chest pain, dizziness, or syncope can impact driving fitness. Due to a growing number of private drivers aged 65 and older and an increasing prevalence of cardiovascular diseases, questions regarding driving fitness restrictions for cardiological patients are gaining prominence in clinical settings. This article aims to summarize current recommendations for driving fitness in the context of cardiovascular diseases. The basis for the guidelines includes the Driving License Ordinance, the expert assessment guidelines of the Federal Highway Research Institute, and the guidelines of the German Society of Cardiology on driving fitness. Original literature on this topic is limited.Emphasizing an individualized assessment, clear guidelines for driving fitness in cardiac diseases or their symptoms and treatments are formulated. Regardless of the cardiac condition, the symptoms and likelihood of sudden loss of consciousness play a leading role in driving fitness assessment. Resulting impairments can range from a few weeks to a complete revocation of driving fitness. Regular examinations and differentiated assessments by medical professionals are prerequisites for maintaining driving fitness.The driving fitness of older private drivers is a significant and practical topic in cardiology. Current guidelines support the treating physicians in providing appropriate recommendations.
Systems and methods for the quantification of sample set quality is provided. In some embodiments, a sample dataset and a sample vector set are received. A rule-based screening of the sample dataset is applied to generate a heuristic quality score. Additionally, a sample vector set is generated from the sample dataset. The difference between the sample vector set and the example vector set is calculated to generate a degree of difference quality score. The heuristic quality score and the degree of difference quality score are normalized and then combined into a quality metric. Calculating the difference between the sample vector set and the example vector set is by framing the distance as a p-value in a hypothesis test, compared against a threshold.
PURPOSE:To obtain human interleukin 1 having physiological activity such as immune response, etc., by cultivating a bacterium transformed with a plasmid integrated with a specific cloned DNA. CONSTITUTION:Culture preparation using a human leukemia cell as an origin is carried out, to give cloned DNA to code human interleukin 1. Then, it is integrated into a plasmied to give a transformed vector, which is transduced into E.coliHB101, to give a transformant. Then, the transformant is precultivated, part of it is inoculated into modified medium M9 such as Casamino acid, etc., cultivated at 37 deg.C for about one hour, a given amount of indole-3-acetic acid is added to the culture mixture, and it is further cultivated for about 24hr. Then, the culture solution is centrifuged, molds are collected, the molds are resuspended in a buffer solution, freezing in a dry ice and/or ethanol bath and melting at about 37 deg.C are repeated about 6 times. Then, the solution is centrifuged to give a supernatant solution, which is treated to polypeptide of human interleukin 1.
It has been unexpectedly found that human oocytes lack the important spindle-associated protein KIFC/HSET. The present application describes a method for stabilizing the human spindle with KIFC/HSET. In particular, the method involves introducing (i) KIFC/HSET protein or (ii) mRNA encoding KIFC/HSET into a human oocyte. Furthermore, the present application relates to a non-naturally occurring human oocyte, wherein (i) KIFC/HSET protein or (ii) KIFC/HSET mRNA has been introduced into the naturally occurring human oocyte, thereby obtaining a non-naturally occurring oocyte. In addition, the present application relates to (i) KIFC/HSET protein or (ii) mRNA encoding KIFC/HSET for use in a method for reducing the probability that a human zygote has disorder and/or multipolar spindles during mitosis by introducing (i) KIFC1/HSET protein or (ii) mRNA encoding KIFC/HSET into the human zygote. Furthermore, complexes are disclosed comprising (i) KIFC/HSET protein and (ii) a human meiotic spindle or a human mitotic spindle, wherein KIFC/HSET protein has been introduced into a human oocyte or zygote.
* Ensure accuracy when prescribing, dispensing, and administering Methadone Hydrochloride Oral Solution to avoid dosing errors due to confusion between mg and mL, and with other methadone hydrochloride oral solutions of different concentrations, which could result in accidental overdose and death. Ensure the proper dose is communicated and dispensed. When writing prescriptions, include both the total dose in mg and the total dose in volume. 
  * Always use a calibrated measuring device when administering Methadone Hydrochloride Oral Solution to ensure the dose is measured and administered accurately. Healthcare providers should recommend a dropper that can measure and deliver the prescribed dose accurately, and instruct caregivers to use extreme caution in measuring the dosage. 
  * The peak respiratory depressant effect of methadone occurs later and persists longer than its peak therapeutic effect.
  * A high degree of opioid tolerance does not eliminate the possibility of methadone overdose, iatrogenic or otherwise. Deaths have been reported during conversion to methadone from chronic, high-dose treatment with other opioid agonists and during initiation of methadone treatment of addiction in subjects previously abusing high doses of other agonists.
  * With repeated dosing, methadone is retained in the liver and then slowly released, prolonging the duration of potential toxicity.
  * Methadone has a narrow therapeutic index, especially when combined with other drugs.
Membranous nephropathy (MN) is a leading cause of kidney failure worldwide and frequently recurs after transplant. Available data originated from small retrospective cohort studies or registry analyses; therefore, uncertainties remain on risk factors for MN recurrence and response to therapy. Within the Post-Transplant Glomerular Disease Consortium, we conducted a retrospective multicenter cohort study examining the MN recurrence rate, risk factors, and response to treatment. This study screened 22,921 patients across 3 continents and included 194 patients who underwent a kidney transplant due to biopsy-proven MN. The cumulative incidence of MN recurrence was 31% at 10 years posttransplant. Patients with a faster progression toward end-stage kidney disease were at higher risk of developing recurrent MN (hazard ratio [HR], 0.55 per decade; 95% confidence interval [CI], 0.35-0.88). Moreover, elevated pretransplant levels of anti-phospholipase A2 receptor (PLA2R) antibodies were strongly associated with recurrence (HR, 18.58; 95% CI, 5.37-64.27). Patients receiving rituximab for MN recurrence had a higher likelihood of achieving remission than patients receiving renin-angiotensin-aldosterone system inhibition alone. In sum, MN recurs in one-third of patients posttransplant, and measurement of serum anti-PLA2R antibody levels shortly before transplant could aid in risk-stratifying patients for MN recurrence. Moreover, patients receiving rituximab had a higher rate of treatment response.
Isolated embryonic stem cells are produced by first, inserting a human or mammalian cell or cell nucleus into enucleated oocytes of an animal species different from the human donor cell, to form a nuclear transfer unit.  The resultant units are activated by exposure to ionomycin and DMAP, and cultured on a feeder cell layer comprising fibroblasts.  Cells obtained from the cultured NT units are used to obtain isolated embryonic stem cells. The human donor cell may be an epithelial cell or lymphocyte, and the animal oocyte may be an ungulate selected from the group of bovine, ovine, porcine, equine, capine and buffalo. The embryonic stem cells may be used for producing desired differentiated cells.  The cells may be manipulated by introduction, removal or modification of desired genes by homologous recombination.   A desired gene may be one that encodes a therapeutic enzyme, growth factor or cytokine. The cells may be used in cell transplantation therapies and for in vitro study of cell differentiation.  Specific examples of conditions wherein cell transplantation therapy may be applied are Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, burns, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.
The invention relates to the medical technical field and provides 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-(piperidine oxadiazole side chain substituted)-2-propanol compounds in one category. The compound comprises cis-trans-isomers thereof and any mixtures in the forms or pharmaceutical salts thereof. The chemical structural formula of the compound is represented by a formula (I). The invention further provides a preparation method for the compound and an application of the compound in preparing antifungal drugs. From an antifungal experiment, the compound provided by the invention has a very strong antifungal effect on various superficial fungi and deep fungi. Compared with existing clinically applied antifungal drugs such as fluconazole, the compound has the advantages of being efficient, low in toxicity and wide in antifungal spectrum, has relatively good activity on fluconazole drug-resistant bacteria and can be used for preparing antifungal drugs. The formula is shown in the description.
a. Invention: Medical use of synthetic peptide carrying ammine-acidssequence WSPCSVTCG of Thrombospondin related anonymous Protein (TRAP) of Plasmodium falciparum. They have adhesive qualities and fight the identification between TRAP and its receptor, inhibiting the growth of the parasite in vitro.b. Application: The synthetic peptides carrying the amine acids sequences WxxWSPCSVTCGxGxRxRxR (TRAP PEP n.), WxxWTSCSTSCGxGxQxRxR (TSPI PEP n.), and WxxWDICSVTCGxGxQxRxR (TSP PEP n.) (x can be any amine acid) fight the molecular identification of the proteins carrying and their ligands and receptors. Examples:1. Control of the Plasmodium falciparum infection by fighting TRAP and its receptor.2. Treatment and prevention of blood-vessels occlusion by fighting the identification of Thrombospondin with its ligands and receptors.3. Prevention of tumours metastasis by fighting the identification of Thrombospondin with its ligands and receptors.
Many chronic inflammatory diseases are attributed to disturbances in host-microbe interactions, which drive immune-mediated tissue damage. Depending on the anatomic setting, a chronic inflammatory disease can exert unique local and systemic influences, which provide an exceptional opportunity for understanding disease mechanism and testing therapeutic interventions. The oral cavity is an easily accessible environment that allows for protective interventions aiming at modulating the immune response to control disease processes driven by a breakdown of host-microbe homeostasis. Periodontal disease (PD) is a prevalent condition in which quantitative and qualitative changes of the oral microbiota (dysbiosis) trigger nonresolving chronic inflammation, progressive bone loss, and ultimately tooth loss. Here, we demonstrate the therapeutic benefit of local sustained delivery of the myeloid-recruiting chemokine (C-C motif) ligand 2 (CCL2) in murine ligature-induced PD using clinically relevant models as a preventive, interventional, or reparative therapy. Local delivery of CCL2 into the periodontium inhibited bone loss and accelerated bone gain that could be ascribed to reduced osteoclasts numbers. CCL2 treatment up-regulated M2-macrophage and downregulated proinflammatory and pro-osteoclastic markers. Furthermore, single-cell ribonucleic acid (RNA) sequencing indicated that CCL2 therapy reversed disease-associated transcriptomic profiles of murine gingival macrophages via inhibiting the triggering receptor expressed on myeloid cells-1 (TREM-1) signaling in classically activated macrophages and inducing protein kinase A (PKA) signaling in infiltrating macrophages. Finally, 16S ribosomal ribonucleic acid (rRNA) sequencing showed mitigation of microbial dysbiosis in the periodontium that correlated with a reduction in microbial load in CCL2-treated mice. This study reveals a novel protective effect of CCL2 local delivery in PD as a model for chronic inflammatory diseases caused by a disturbance in host-microbe homeostasis.
Yoga preference arm consists of participants who are randomized to the preference condition and choose to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
Pancreatic cancer is still a difficult disease to treat, despite recent advances in surgical techniques and chemotherapeutic drugs. Its incidence continues to rise, as does the number of older patients. Sarcopenia is defined as a progressive and generalized loss of skeletal muscle mass and strength. Sarcopenia is present in approximately 40% in patients with pancreatic cancer. Sarcopenia is primarily diagnosed through imaging, and progress is being made in the development of automated methods and artificial intelligence, as well as biomarker research. Sarcopenia has been linked to a poor prognosis in pancreatic cancer patients. However, some studies suggest that sarcopenia is not always associated with a poor prognosis, depending on the resectability of pancreatic cancer and the nature of treatment, such as surgery or chemotherapy. Recent meta-analyses have found that sarcopenia is not linked to postoperative complications. It is still debated whether there is a link between sarcopenia and drug toxicity during chemotherapy. The relationship between sarcopenia and immunity has been investigated, but the mechanism is still unknown.
The invention belongs to the field of medicament preparation and discloses a fenofibrate osmotic pump type controlled release preparation and a preparation method thereof. The preparation is formed by an osmotic pump tablet core and a controlled release coat coated outside the tablet core. The weight of the osmotic pump controlled release tablet core is as follows: 250mg/tablet of fenofibrate, 25mg to 100mg/tablet of osmotic active matter, 200mg of 300mg/tablet of accessory which can lead the medicament in a medicine containing layer to be easily released, 75 to 150mg/tablet of accessory which leads the medicament to be easily released in a promoting layer and proper amount of other accessories. The weight of the osmotic pump coat is as follows: 15g to 30g/100 tablets of semi-transparent membrane coat macromolecule material and 2 to 10g/100 tablets of pore-foaming agent. The invention can effectively adjust the release speed of the medicament by adjusting the tablet core and the prescription of the coat and obtain more stable and durable effective blood medicine concentration, thereby reducing the side effect and the taking times of the medicament, ensuring that the suction of the medicament is not affected by whether the patient eats or not and the environment in a body, and improving the compliance of a sufferer. The invention can be broadly applied to curing hyperlipemia.
Tiofucºsidos containing polihidroxialquil-furanos. Synthesis and uses thereof. A compound comprising a thiophostoside containing polyhydroxyalkyl furans. The invention also relates to the method of obtaining said compound and its application in the treatment of disorders or disorders involving selectins, such as, for example, inflammatory processes, cancer, arthritis, thrombosis, dermatitis, inflammations, lungs or heart conditions. . (Machine-translation by Google Translate, not legally binding)
Low-level laser therapy has been practiced for about 20 years in Europe and is beginning to be practiced in the US. Theoretically, laser energy in the red and near infrared light spectrum is capable of penetrating 2-5 cm into tissue and can stimulate mitochondria in the cells to produce more energy (through the production of adenosine triphosphate), which in turn may help prevent or repair tissue damage. The effects of low-level laser therapy on hearing have not been well studied. It has been suggested that laser therapy might help repair damage to the cochlea and restore some degree of hearing loss. Studies of low-level laser stimulation of cochleae utilizing microscopy, PET imaging, and MRI suggest potential therapeutic benefit to hearing. While preliminary studies suggest a possible improvement in hearing thresholds, a carefully controlled study is needed to verify the results using a valid battery of audiological tests.
Patients receive placebo PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.